Welcome to our dedicated page for Microbot Med news (Ticker: MBOT), a resource for investors and traders seeking the latest updates and insights on Microbot Med stock.
Microbot Medical develops and distributes the LIBERTY Endovascular Robotic System, an FDA-cleared, single-use, remotely operated robotic system for peripheral endovascular procedures. Company news centers on the system’s U.S. commercialization, adoption by healthcare institutions, use across peripheral endovascular case types, and clinical evidence from the ACCESS-PVI pivotal study.
Updates also cover medical-society guidance on radiation exposure and ergonomics in interventional radiology, conference presentations to healthcare and financial audiences, and commercial readiness outside the United States. The company frames LIBERTY around robotic vascular navigation and the need to address radiation exposure and physical strain for interventional teams.
Microbot Medical Inc. (NASDAQ: MBOT) will host a webinar on August 26, 2020, at 11:00 AM ET, following a successful presentation at the Needham Virtual Med Tech & Diagnostic Conference. CEO Harel Gadot will discuss the LIBERTYTM Robotic System, which has achieved all endpoints in a recent feasibility animal study with no adverse events. The system's capabilities may enable catheter-based procedures to be performed remotely, enhancing clinical outcomes while minimizing risks like radiation exposure. Management will also address audience questions during the session.
Microbot Medical Inc. (Nasdaq: MBOT) will present initial results from a feasibility animal study of its LIBERTY Robotic System at the Needham Virtual Med Tech & Diagnostics Conference on August 17, 2020. The LIBERTY system is the first fully disposable robotic system designed to reduce radiation exposure for physicians. The company aims to innovate through its proprietary technologies, focusing on micro-robotic solutions within the human body. Further details will be available on their website prior to the conference.